Prof Byoung Yong Shim speaks to ecancer in an online interview for the virtual ELCC 2021 meeting about survival data from EMPOWER-Lung 4. This was a phase 2 study of cemiplimab plus ipilimumab in the second-line treatment of advanced non-small-cell lung cancer (NSCLC).

He explains that the results presented show improvements in overall survival and progression-free survival in patients receiving this combination, and adds that the study - amongst others - shows there is potential to further optimise the treatment of NSCLC with combinations of PD-1 inhibitors and other medicine.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.